Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus epacadostat vs pembrolizumab plus placebo in first-line metastatic NSCLC with high PD-L1
2017-001841-28Phase 2Unknown
- Sponsor
- Incyte
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab plus epacadostat with Pembrolizumab plus placebo (2 arms). Primary endpoints: Objective response rate (ORR) and Progression-free survival (PFS). Status: unknown.
02
Drugs
pembrolizumabepacadostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-001841-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001841-28.